Literature DB >> 6342655

Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes.

K Atkinson, J C Biggs, J Hayes, M Ralston, A J Dodds, A J Concannon, D Naidoo.   

Abstract

Thirty-six patients received allogeneic (34) or syngeneic (two) bone marrow transplants as treatment for severe aplastic anaemia or acute leukaemia. Nineteen of the allogeneic recipients received methotrexate (MTX) and 15 received cyclosporin A (CyA) as the predominant immunosuppressive agent to minimize graft-versus-host disease (GVHD) post transplant. In the first 100 d post transplant renal dysfunction was much less frequent in the MTX recipients than in the CyA recipients who exhibited three distinct syndromes of nephrotoxicity: most commonly. CyA recipients developed asymptomatic azotaemia, proteinuria, urinary casts, impaired urinary concentrating ability and hypertension. Secondly, two CyA recipients developed acute reversible renal failure precipitated by systemic bacterial infection which required dialysis and in which the kidney was the sole target organ; thirdly, two recipients of HLA-genotypically non-identical grafts developed a rapidly progressive fatal syndrome with multiple organ involvement including lung, brain and kidney which clinically and histologically resembled thrombotic thrombocytopenic purpura.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6342655     DOI: 10.1111/j.1365-2141.1983.tb02067.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up.

Authors:  Smita Bhatia
Journal:  Expert Rev Hematol       Date:  2011-08       Impact factor: 2.929

2.  The haemolytic uraemic syndrome and bone marrow transplantation.

Authors:  J I Craig; T Sheehan; K Bell
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-10

3.  Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.

Authors:  J McCauley; O Bronsther; J Fung; S Todo; T E Starzl
Journal:  Lancet       Date:  1989 Dec 23-30       Impact factor: 79.321

Review 4.  Hemostatic changes in patients with malignancy.

Authors:  G H Goldsmith
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

6.  Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.

Authors:  Joseph Rosenthal; Anna Pawlowska; Ellen Bolotin; Cheryl Cervantes; Sean Maroongroge; Sandra H Thomas; Stephen J Forman
Journal:  Pediatr Blood Cancer       Date:  2010-11-23       Impact factor: 3.167

7.  Distribution and concentration of cyclosporin in human blood.

Authors:  K Atkinson; K Britton; J Biggs
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

8.  Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.

Authors:  Siribha Changsirikulchai; David Myerson; Katherine A Guthrie; George B McDonald; Charles E Alpers; Sangeeta R Hingorani
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 8.237

9.  Severe systemic vascular necrosis in cyclosporin-treated rabbits with acute serum sickness.

Authors:  G H Neild; K Ivory; D G Williams
Journal:  Br J Exp Pathol       Date:  1984-12

10.  Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation.

Authors:  Michael Choi; Can-Lan Sun; Seira Kurian; Andrea Carter; Liton Francisco; Stephen J Forman; Smita Bhatia
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.